Arundathy Pandite, the Chief Medical Officer of Shattuck Labs, Inc. (NASDAQ: STTK), has executed a sale of company equity, removing 30,000 shares from her direct holdings. The transaction, finalized on June 30, 2026, carried a total monetary value of $210,300. The shares were divested at prices fluctuating between $6.62 and $7.40 per unit. This activity was conducted pursuant to a Rule 10b5-1 trading plan, which Pandite established on February 2, 2026. Following the execution of this sale, her direct ownership position in Shattuck Labs common stock stands at 136,219 shares.
The insider transaction occurs as Shattuck Labs navigates a period of significant capital structure adjustment and clinical progress. The company recently announced the pricing of a public offering designed to raise approximately $75 million in gross proceeds. This offering structure includes the sale of 10,879,376 shares of common stock, priced at $4.00 per share, alongside pre-funded warrants that allow for the purchase of up to 7,870,624 additional shares at a price of $3.9999 per warrant.
Concurrently, Shattuck Labs has disclosed the receipt of notices to exercise approximately 50.6 million common stock warrants. These exercises are projected to generate anticipated gross proceeds of roughly $54.9 million. This development builds upon recent financial inflows from warrant exercises, including a previous receipt of $5.6 million from the exercise of 5,147,773 warrants. Furthermore, the company anticipates an additional $49.3 million in proceeds from the exercise of 45,438,709 warrants since March 31, 2026.
From a market valuation perspective, Shattuck Labs stock currently trades at $7.05, a level near its 52-week high of $8.33. This pricing reflects a remarkable 746% surge in value over the past year. According to analysis from InvestingPro, the stock appears overvalued at its current levels, leading to its inclusion on the platform’s "Most Overvalued stocks" list. The company's stock performance has drawn attention, with data highlighting strong momentum and comprehensive financial metrics for evaluation.
On the clinical front, Shattuck Labs has reported positive results from a Phase 1 clinical trial for SL-325, its DR3 blocking antibody candidate. The trial data indicated a low immunogenicity profile, with only 3.7% of participants developing antidrug antibodies. While analysts have been monitoring these corporate and clinical developments, no specific upgrades or downgrades have been noted from major research firms. These activities collectively reflect ongoing strategic efforts by Shattuck Labs to bolster its financial position and advance its clinical-stage programs.